ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Evaluation of Renal Function After a Transition to Everolimus or Mycophenolate Mofetil in Liver Transplant Recipients.

C. Perez,1 J. Fleming,1 M. Sell,1 B. O'brien,1 A. Rogers,1 I. Lee,1 C. Mardis,1 A. Mardis,1 N. Patel,1 H. Meadows,1 N. Pilch,2 K. Chavin,2 D. Dubay,2 R. Vinayak,2 D. Taber.2

1Pharmacy, Medical University of South Carolina, Chareleston, SC
2Surgery, Medical University of South Carolina, Charleston, SC

Meeting: 2017 American Transplant Congress

Abstract number: D200

Keywords: Immunosuppression, Liver transplantation

Session Information

Date: Tuesday, May 2, 2017

Session Name: Poster Session D: Liver: Immunosuppression and Rejection

Session Time: 6:00pm-7:00pm

 Presentation Time: 6:00pm-7:00pm

Location: Hall D1

Related Abstracts
  • Concomitant Proton Pump Inhibitor and Mycophenolate Mofetil Use in Renal Transplant Recipients.
  • Everolimus versus Mycophenolate Mofetil in Combination with Tacrolimus: A Propensity Score Matching Analysis in Liver Transplantation.

Purpose: The aim of this study was to assess if there is a difference in renal function over time when transitioning to everolimus vs. mycophenolate.

Methods: This was a retrospective cohort study of adult OLTx patients between Jan 2010 through Dec 2015. All patients who were transitioned to either everolimus or mycophenolate from CNI-based regimen by post-op day 90 as CNI minimization or withdrawal were included. Multiorgan transplant patients were excluded. The primary outcome was renal function at 2-year post-transplant using MDRD. Other outcomes included discontinuation of therapy, rejection, complications, reoperations, infections, HCV recurrence, malignancy, disease recurrence, retransplant, lab findings, graft loss, and death.

Results: A total of 96 patients were included. Baseline characteristics were similar between groups, with differences noted in primary insurance, presence of HCC, NASH as etiology of ESLD, functional status, and MELD score (Table 1). Based on the change in eGFR slope overtime, there was a trend towards worsening renal function in the everolimus group at 1-year post-transplant (Table 2 & Figure 1, p=0.081). Discontinuation of therapy occurred in 15 (54%) patients in the everolimus group versus 26 (38%) in the mycophenolate group (p=0.167). There was no difference between groups in other clinical outcomes (Table 3, Table 4 & Figure 2). Conclusion: This data demonstrates that the adjunctant use of everolimus, as compared to mycophenolate in liver transplant recipients, produced a trend toward worsening renal function and higher discontinuation rates with similar clinical outcomes.

CITATION INFORMATION: Perez C, Fleming J, Sell M, O'brien B, Rogers A, Lee I, Mardis C, Mardis A, Patel N, Meadows H, Pilch N, Chavin K, Dubay D, Vinayak R, Taber D. Evaluation of Renal Function After a Transition to Everolimus or Mycophenolate Mofetil in Liver Transplant Recipients. Am J Transplant. 2017;17 (suppl 3).

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Perez C, Fleming J, Sell M, O'brien B, Rogers A, Lee I, Mardis C, Mardis A, Patel N, Meadows H, Pilch N, Chavin K, Dubay D, Vinayak R, Taber D. Evaluation of Renal Function After a Transition to Everolimus or Mycophenolate Mofetil in Liver Transplant Recipients. [abstract]. Am J Transplant. 2017; 17 (suppl 3). https://atcmeetingabstracts.com/abstract/evaluation-of-renal-function-after-a-transition-to-everolimus-or-mycophenolate-mofetil-in-liver-transplant-recipients/. Accessed April 20, 2021.

« Back to 2017 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes
  • Penis Transplantation: First U.S. Experience.
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Live Related Kidney Transplant Experience in Abuja, Nigeria – First Eight Cases Ever.
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.